Health Care: Pharmaceuticals/Specialty
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Health Care: Pharmaceuticals/Specialty

Aaron (Ronny) Gal rises one rung to finish in first place for the first time, partly on the strength of what one ­money ­manager.

100x102-galaaron.jpg
Aaron (Ronny) Gal Sanford C. Bernstein


second team Gregory Gilbert BofA Merrill Lynch


third team David Steinberg Deutsche


Aaron (Ronny) Gal rises one rung to finish in first place for the first time, partly on the strength of what one ­money ­manager calls “spectacular, high-­conviction stock picking, especially where Allergan is concerned.” The 42-year-old ­Sanford C. Bernstein analyst first recommended the Irvine, California–based manufacturer way back in 2006. He has been high­lighting his position ever since, telling clients that clinical applications for Botox go far beyond wrinkle removal and when the drug’s full potential is realized, Allergan’s share price will soar. Last fall the company reported that it had achieved positive results in its own testing of Botox as a treatment for migraine headaches and plans to apply to the FDA for a supplemental license application by the end of this year. Allergan’s stock rose 38.7 percent year-to-date through August, far ahead of the sector’s anemic 2.5 percent advance. Gal earned a Ph.D. in chemistry from the Massachusetts Institute of Technology in 1996 and worked as a pharmaceuticals consultant at Boston Consulting Group before joining Bernstein in 2005.


BofA Merrill’s Gregory ­Gilbert, who slips one notch to second place, has built “some of the best pricing models out there,” according to one investor. Gilbert upgraded Par Pharmaceutical Cos. to buy in April, at $10.93, as the Woodcliff La, New Jersey, generic-­drug maker was dumping unprofitable brands to focus on products with greater sales potential. The stock had skyrocketed 87.1 percent, to $20.45, by late August.


David Steinberg of Deutsche Bank rises one rung to third place. The San ­Francisco–based analyst reiterated his yearlong buy on Teva Pharmaceutical Industries in July 2008, after the Israeli generic-­drug manufacturer announced plans to acquire Barr Pharmaceuticals of Montvale, New Jersey; Steinberg thought the match made good sense. Teva’s stock advanced 23.3 percent since the reiteration, through August 2009.


Click here to see the All-America Research Team rankings.


Related

In changing times, Mislav Matejka and his equity strategy team at J.P. Morgan are big vote-getters on the 2017 All-Europe Research Team.
BTG Pactual lands in second place for a second consecutive year.
Bank of America Merrill Lynch advances to second place; BTG Pactual tumbles to third.
Gift this article